Value proposition

Personalized & bioengineered human skin tissue therapy for patients with severe burns and skin injuries

Our mission: to give patients back more of their own skin to make them well again.

CUTISS is a Swiss clinical-stage life sciences company focussed on regenerative medicine, skin tissue engineering, and skin pigmentation.

We are developing the first personalized and automated skin tissue therapy offering life-saving and life-changing medical treatments for patients with severe skin injuries.

Our lead product denovoSkin promises to take skin surgery to the next level and revolutionize current treatments. It is a bio-engineered and personalized dermo-epidermal human skin graft, currently in Phase 2 clinical trials in Switzerland and the European Union. It has Orphan Drug Designation for the treatment of burns from Swissmedic, EMA, and FDA.

CUTISS is also developing the world’s first machine that can automate the entire production process of the personalised skin graft.

Our company’s knowledge in skin bio-engineering and biology offers other growth opportunities in regenerative medicine, and also beyond the medical domain.

Established in 2017, CUTISS is a spin-off from University of Zurich (UZH) / University Children’s Hospital. We successfully exited the Wyss Zurich accelerator in 2022.

Headquartered at the Bio-Technopark in Zurich, CUTISS won the Top 100 Swiss Startup Award 2020, and has raised over CHF 90 million from private investors, family offices and public bodies.